[go: up one dir, main page]

SA520411662B1 - بروتينات التحام تشتمل على إنزيمات علاج بديل للإنزيم - Google Patents

بروتينات التحام تشتمل على إنزيمات علاج بديل للإنزيم

Info

Publication number
SA520411662B1
SA520411662B1 SA520411662A SA520411662A SA520411662B1 SA 520411662 B1 SA520411662 B1 SA 520411662B1 SA 520411662 A SA520411662 A SA 520411662A SA 520411662 A SA520411662 A SA 520411662A SA 520411662 B1 SA520411662 B1 SA 520411662B1
Authority
SA
Saudi Arabia
Prior art keywords
fusion proteins
replacement therapy
enzyme replacement
proteins include
include enzymes
Prior art date
Application number
SA520411662A
Other languages
English (en)
Inventor
جيوسيب استاريتا
جولى اولمان
جينيفير ايه جيتز
مارك اس دينيس
جوى يو زوشيرو
انكيتا سريفاستافا
ادم بى سيلفيرمان
ميهاليس كاريوليس
كاثال ماهون
اناستاسيا هينرى
جونهوا وانج
Original Assignee
دينالى ثيرابيتوتيكس إنك
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by دينالى ثيرابيتوتيكس إنك filed Critical دينالى ثيرابيتوتيكس إنك
Publication of SA520411662B1 publication Critical patent/SA520411662B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01001—Carboxylesterase (3.1.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يقدم الاختراع الحالي بروتينات التحام fusion proteins تشتمل على إنزيم enzyme علاج بديل إنزيم enzyme replacement therapy ومنطقة شظية قابلة للتبلر crystallizable fraction (Fc)، فضلاً عن طرق استخدام تلك البروتينات proteins لعلاج اضطراب تخزين جسيم حال lysosomal storage disorder. كما يوفر الاختراع الحالي طرق لنقل عوامل عبر حاجز دماغي دموي blood-brain barrier. شكل1 شكل1
SA520411662A 2017-10-02 2020-03-30 بروتينات التحام تشتمل على إنزيمات علاج بديل للإنزيم SA520411662B1 (ar)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762566898P 2017-10-02 2017-10-02
US201762583276P 2017-11-08 2017-11-08
US201862626365P 2018-02-05 2018-02-05
US201862678183P 2018-05-30 2018-05-30
US201862721396P 2018-08-22 2018-08-22
PCT/US2018/053747 WO2019070577A1 (en) 2017-10-02 2018-10-01 FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES

Publications (1)

Publication Number Publication Date
SA520411662B1 true SA520411662B1 (ar) 2023-12-03

Family

ID=64267892

Family Applications (1)

Application Number Title Priority Date Filing Date
SA520411662A SA520411662B1 (ar) 2017-10-02 2020-03-30 بروتينات التحام تشتمل على إنزيمات علاج بديل للإنزيم

Country Status (21)

Country Link
US (3) US20200277584A1 (ar)
EP (2) EP3904389A1 (ar)
JP (2) JP2021500857A (ar)
KR (1) KR20200058510A (ar)
CN (1) CN111278859A (ar)
AU (1) AU2018345303B2 (ar)
BR (1) BR112020005271A2 (ar)
CA (1) CA3076369A1 (ar)
CL (1) CL2020000810A1 (ar)
CO (1) CO2020003128A2 (ar)
CR (1) CR20200129A (ar)
IL (1) IL273439B2 (ar)
MA (1) MA50746A (ar)
MX (3) MX2020002918A (ar)
MY (1) MY209029A (ar)
PE (1) PE20210347A1 (ar)
PH (1) PH12020550510A1 (ar)
SA (1) SA520411662B1 (ar)
SG (1) SG11202002730XA (ar)
TW (1) TW201925236A (ar)
WO (1) WO2019070577A1 (ar)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3583120T3 (fi) 2017-02-17 2023-01-13 Muunneltuja transferriinireseptoria sitovia polypeptidejä
CA3076369A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
SG11202101273VA (en) * 2018-08-16 2021-03-30 Denali Therapeutics Inc Engineered bispecific proteins
MA54450A (fr) 2018-12-10 2021-10-20 Denali Therapeutics Inc Biomarqueurs de maladie lysosomale et leurs méthodes d'utilisation
EP3927743A1 (en) 2019-02-20 2021-12-29 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
MX2021011612A (es) * 2019-04-03 2021-12-10 Denali Therapeutics Inc Formulaciones de moleculas proteicas que comprenden iduronato 2-sulfatasa.
CN110111326B (zh) * 2019-05-15 2021-01-15 西安科技大学 基于ert系统的重建图像质量评价方法
AU2020411480B2 (en) 2019-12-23 2023-12-21 Denali Therapeutics Inc. Progranulin variants
KR20220131246A (ko) 2020-01-13 2022-09-27 데날리 테라퓨틱스 인크. 항-trem2 항체 및 이의 사용 방법
EP4100419A4 (en) * 2020-02-07 2024-05-29 Denali Therapeutics Inc. METHODS OF TREATING HUNTER SYNDROME
MA71661A (fr) 2020-10-14 2025-05-30 Denali Therapeutics Inc. Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées
KR20220073454A (ko) * 2020-11-26 2022-06-03 한미약품 주식회사 신규한 뇌 표적 지속형 단백질 결합체 및 이의 제조방법
CN116997364A (zh) * 2021-02-11 2023-11-03 戴纳立制药公司 抗转铁蛋白受体融合蛋白及其使用方法
WO2023004156A1 (en) 2021-07-23 2023-01-26 Denali Therapeutics Inc. Methods for the treatment of hunter syndrome
AU2022415476A1 (en) 2021-12-17 2024-07-04 Denali Therapeutics Inc. Fusion proteins comprising alpha-l-iduronidase enzymes and methods
EP4508206A1 (en) * 2022-04-12 2025-02-19 F. Hoffmann-La Roche AG Fusion proteins targeted to the central nervous system
JP2025517360A (ja) * 2022-05-16 2025-06-05 デナリ セラピューティクス インコーポレイテッド トランスフェリン受容体結合ドメイン及びそれを含むタンパク質
WO2023244540A1 (en) 2022-06-13 2023-12-21 Denali Therapeutics Inc. A quantitative pharmacological model of enzyme replacement therapy
CN115032377B (zh) * 2022-08-11 2022-11-01 裕菁科技(上海)有限公司 一种粘多糖贮积症生物标记物及应用
WO2024211624A1 (en) * 2023-04-04 2024-10-10 University Of Cincinnati Novel treatment strategies for pancreatic cancer using recombinant acid sphingomyelinase
WO2024220986A2 (en) 2023-04-21 2024-10-24 Denali Therapeutics Inc. Methods of increasing sialic acid levels in recombinant glycosylated proteins
WO2025137213A1 (en) 2023-12-20 2025-06-26 Denali Therapeutics Inc. Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof
WO2025166045A1 (en) * 2024-01-31 2025-08-07 Alector Llc β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ATE384736T1 (de) 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
EP2399586A1 (en) 2002-01-11 2011-12-28 Jefferies, Dr., Wilfred Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050142141A1 (en) * 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
EP1592786B8 (en) 2003-02-11 2012-03-21 Shire Human Genetic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies using a formylglycine generating enzyme (fge)
US20040258666A1 (en) 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
AU2003286870A1 (en) 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
JP4762904B2 (ja) 2003-11-13 2011-08-31 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン不変領域の量産方法
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP2532742B1 (en) 2004-01-30 2018-08-08 Shire Pharmaceuticals Ireland Limited Recombinant arylsulfatase A for reducing galatosyl sulphatide levels in a subject
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
PL1699826T3 (pl) 2005-01-05 2009-08-31 F Star Biotechnologische Forschungs Und Entw M B H Syntetyczne domeny immunoglobulinowe o właściwościach wiążących modyfikowane w regionach cząsteczki różnych od regionów determinujących komplementarność
WO2006108052A2 (en) 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
EP1981546B1 (en) 2006-02-06 2014-06-04 The Medical Research and Infrastructure Fund of the Tel-Aviv Sourasky Medical Center Enzyme replacement therapy for treating lysosomal storage diseases
US8748567B2 (en) 2006-05-22 2014-06-10 Children's Medical Center Corporation Method for delivery across the blood brain barrier
US7871624B2 (en) * 2006-06-27 2011-01-18 Saint Louis University Chimeral polypeptide composition for cross-placenta delivery
WO2008105796A2 (en) 2006-06-29 2008-09-04 Albert Einstein College Of Medicine Of Yeshiva University Compounds and methods for detecting ricin and uses thereof
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
WO2008089339A2 (en) 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharide conjugates for cellular targeting
CA3112632A1 (en) 2008-01-18 2009-07-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
WO2009137721A2 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
BR112012004377A2 (pt) 2009-08-28 2017-12-12 Genzyme Corp terapia de reposição enzimática com progressão de dose para tratamento de deficiência de esfingomielinase ácida.
ES2783024T3 (es) 2009-09-29 2020-09-16 Univ Gent Hidrólisis de la unión de manosa-1-fosfo-6-manosa a fosfo-6-manosa
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
LT2588130T (lt) 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
PL3626258T3 (pl) 2010-06-25 2022-01-17 Shire Human Genetic Therapies, Inc. Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun
AU2011274229A1 (en) 2010-07-02 2013-01-10 Angiochem Inc. Short and D-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
EP2622089B1 (en) 2010-09-29 2023-11-01 Oxyrane UK Limited De-mannosylation of phosphorylated n-glycans
CN103154243A (zh) 2010-10-15 2013-06-12 日本化学研究株式会社 糖链的非还原末端为甘露糖残基的糖蛋白的制造方法
JP5913122B2 (ja) 2010-11-08 2016-04-27 Ｊｃｒファーマ株式会社 新規発現ベクター
KR102188544B1 (ko) 2010-11-30 2020-12-08 제넨테크, 인크. 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도
EP2654800B1 (en) 2010-12-22 2017-12-06 Fondazione Telethon Therapeutic strategies to treat cns pathology in mucopolysaccharidoses
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
WO2012136790A1 (en) * 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9880151B2 (en) 2011-05-23 2018-01-30 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
CA2836318C (en) 2011-05-27 2018-11-27 Callidus Biopharma, Inc. Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases
US9845327B2 (en) 2011-06-22 2017-12-19 The General Hospital Corporation Treatment of proteinopathies
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
DK2739649T3 (en) 2011-08-05 2018-01-08 Bioasis Technologies Inc P97 FRAGMENTS WITH TRANSFER ACTIVITY
MX2014004359A (es) 2011-10-12 2014-05-28 Synageva Biopharma Corp Proteina naglu humana recombinante y usos de la misma.
US20150037311A1 (en) 2011-12-01 2015-02-05 Angiochem Inc. Targeted lysosomal enzyme compounds
BR112014013250A2 (pt) 2011-12-01 2019-09-24 Angiochem Inc compostos com enzima alvo e usos dos mesmos
EP2785378B1 (en) 2011-12-02 2020-05-13 Armagen, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
BR112014015352A8 (pt) 2011-12-23 2017-06-13 Shire Human Genetic Therapies tratamento de comprometimento cognitivo da síndrome de hunter por distribuição intratecal de iduronato-2-sulfatase
WO2013148277A1 (en) 2012-03-30 2013-10-03 Shire Human Genetic Therapies, Inc. Subcutaneous administration of iduronate- 2-sulfatase
CA2871468C (en) 2012-04-23 2021-09-21 Nrl Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
JP6279466B2 (ja) 2012-04-27 2018-02-14 Ｊｃｒファーマ株式会社 新規な発現ベクター
US20150353639A1 (en) 2012-05-21 2015-12-10 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
EP2854834A4 (en) 2012-05-30 2016-05-18 Biostrategies LC PLANT LENSES AS CARRIER CORRESPONDING AGENTS IN ANIMAL AND HUMAN CELLS
WO2013184514A1 (en) 2012-06-04 2013-12-12 Irm Llc Site-specific labeling methods and molecules produced thereby
CN104662151A (zh) 2012-06-15 2015-05-27 安吉奥开米公司 靶向的艾杜糖醛酸酶化合物
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
AU2013296557B2 (en) 2012-07-31 2019-04-18 Bioasis Technologies Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
US10138474B2 (en) 2012-08-17 2018-11-27 Research Foundation Of The City University Of New York Scavenger receptor uptake for fabry disease enzyme replacement therapy
HUE045144T2 (hu) 2012-08-29 2019-12-30 Hoffmann La Roche Véragygát-shuttle
WO2014082080A2 (en) 2012-11-26 2014-05-30 Callidus Biopharma, Inc. Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases
ES2679374T3 (es) 2012-11-27 2018-08-24 Biomarin Pharmaceutical Inc. Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
US20150290341A1 (en) 2012-11-30 2015-10-15 Anglachem Inc. Targeted iduronate-2-sulfatase compounds
US10210288B2 (en) 2012-12-27 2019-02-19 Schneider Electric It Corporation Systems and methods of visualizing airflow
EP2970433B1 (en) 2013-03-13 2019-09-18 Bioasis Technologies Inc. Fragments of p97 and uses thereof
EP3431592A1 (en) 2013-03-14 2019-01-23 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
PH12021550015A1 (en) 2013-05-20 2022-05-11 Genentech Inc Anti-transferrin receptor antibodies and methods of use
WO2014194427A1 (en) 2013-06-06 2014-12-11 Angiochem Inc. Targeted iduronate-2-sulfatase fusion proteins
KR102228367B1 (ko) 2013-06-07 2021-03-16 젠자임 코포레이션 산 스핑고미엘리나제 장애에 대한 마커 및 이의 용도
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
US10906981B2 (en) 2013-07-19 2021-02-02 The Regents Of The University Of California Compositions and methods related to structures that cross the blood brain barrier
EP3024848B1 (en) 2013-07-22 2020-07-08 Armagen, Inc. Methods and compositions for increasing enzyme activity in the cns
EP3038657A2 (en) * 2013-08-28 2016-07-06 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
US11261262B2 (en) 2013-09-03 2022-03-01 Novimmune Sa Readily isolated bispecific binding molecules with native format having mutated constant regions
JP6309427B2 (ja) 2013-10-09 2018-04-11 Ｊｃｒファーマ株式会社 イズロン酸−２−スルファターゼの活性測定法
WO2015098989A1 (ja) 2013-12-25 2015-07-02 Ｊｃｒファーマ株式会社 血液脳関門を通過する新規抗トランスフェリン受容体抗体
ES2895752T3 (es) 2014-01-03 2022-02-22 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
ES2864160T3 (es) 2014-01-06 2021-10-13 Hoffmann La Roche Módulos lanzadera de la barrera hematoencefálica monovalentes
EP3107562B1 (en) 2014-02-19 2019-09-18 Bioasis Technologies Inc. P97-ids fusion proteins
SMT201800511T1 (it) 2014-04-01 2018-11-09 Swedish Orphan Biovitrum Ab Publ Sulfamidasi modificata e sua produzione
JP6847664B2 (ja) 2014-05-01 2021-03-24 バイオアシス テクノロジーズ インコーポレイテッド Ｐ９７−ポリヌクレオチド複合体
EP3166626B1 (en) 2014-07-11 2021-04-28 Biostrategies LC Materials and methods for treating disorders associated with sulfatase enzymes
US10068619B1 (en) 2014-07-25 2018-09-04 Western Digital Technologies, Inc. Hand held storage device
EP3185889B1 (en) 2014-08-11 2020-07-15 Shire Human Genetic Therapies, Inc. Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
PT3215528T (pt) 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
EP3218000A2 (en) 2014-11-10 2017-09-20 Alexion Pharmaceuticals, Inc. Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof
CA2967830A1 (en) 2014-11-14 2016-05-19 Ossianix, Inc. Tfr selective binding compounds and related methods
MA40954A (fr) * 2014-11-14 2017-09-19 Shire Human Genetic Therapies Détermination de niveaux de glycosaminoglycane par spectrométrie de masse
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
CN107001473B (zh) * 2014-11-19 2021-07-09 豪夫迈·罗氏有限公司 抗-运铁蛋白受体抗体及使用方法
MA41198A (fr) 2014-12-18 2017-10-24 Shire Human Genetic Therapies Essais d'activité enzymatique pour i2s
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
CA2973343C (en) 2015-02-05 2023-08-08 R.P. Scherer Technologies, Llc Activated formylglycine-generating enzymes and methods of producing and using the same
CA2987684A1 (en) 2015-06-01 2016-12-08 The Hospital For Sick Children Delivery of structurally diverse polypeptide cargo into mammalian cells by a bacterial toxin
US10377582B2 (en) 2015-06-24 2019-08-13 Beumer Group A/S Line sorter
IL302486A (en) * 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
TWI769982B (zh) 2015-06-24 2022-07-11 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
KR20170004814A (ko) 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
WO2017003270A1 (ko) 2015-07-02 2017-01-05 주식회사 녹십자 헌터증후군 치료제 및 치료방법
JP2018534917A (ja) 2015-10-01 2018-11-29 スウェディッシュ オーファン バイオビトラム アクティエボラーグ （ペーウーベーエル） 修飾イズロン酸２−スルファターゼとその製造
CA3000289A1 (en) 2015-10-01 2017-04-06 Swedish Orphan Biovitrum Ab (Publ) Modified lysosomal protein and production thereof
US20180221459A1 (en) 2015-10-06 2018-08-09 LA BioMedical Research Institute at Harbor-UCLA Medical Center Enzyme replacement therapy for mucopolysaccharidosis iiid
WO2017062666A2 (en) 2015-10-06 2017-04-13 Patricia Dickson Enzyme replacement therapy for mucopolysaccharidosis iiid
KR102851747B1 (ko) 2015-12-08 2025-08-28 리제너론 파마슈티칼스 인코포레이티드 효소 내재화 조성물 및 방법
GB201522243D0 (en) 2015-12-16 2016-01-27 Ucl Business Plc Treatment
CN108430494A (zh) 2015-12-30 2018-08-21 株式会社绿十字 用于治疗亨特综合征的方法和组合物
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
EP3419651B1 (en) 2016-02-24 2023-10-25 BioMarin Pharmaceutical Inc. Improved naglu fusion protein formulation
US20190046637A1 (en) 2016-03-01 2019-02-14 Biostrategies LC Materials and methods for mitigating immune-sensitization
IL305449B1 (en) 2016-04-15 2025-09-01 Univ Pennsylvania Gene therapy for the treatment of mucocutaneous type ii diabetes
US10169252B2 (en) 2016-07-15 2019-01-01 International Business Machines Corporation Configuring functional capabilities of a computer system
EP3494216B1 (en) 2016-08-06 2025-10-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
AU2017316955B2 (en) 2016-08-25 2022-03-03 Jcr Pharmaceuticals Co., Ltd. Method for producing antibody fusion protein
EP3556399A1 (en) 2016-12-19 2019-10-23 Hanmi Pharm. Co., Ltd. Brain targeting long-acting protein conjugate
NZ752703A (en) * 2016-12-26 2022-09-30 Japan Chem Res Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
CA3048381A1 (en) 2016-12-28 2018-07-05 Jcr Pharmaceuticals Co., Ltd. Lyophilized preparation
GB201701968D0 (en) 2017-02-07 2017-03-22 Univ Manchester Gene therapy
WO2018152375A2 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Engineered polypeptides
WO2018152359A1 (en) * 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
FI3583120T3 (fi) 2017-02-17 2023-01-13 Muunneltuja transferriinireseptoria sitovia polypeptidejä
WO2018152285A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Transferrin receptor transgenic models
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
WO2018155443A1 (ja) 2017-02-21 2018-08-30 Ｊｃｒファーマ株式会社 グリコサミノグリカンの分析法
GB201702863D0 (en) 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
WO2019009884A1 (en) 2017-07-03 2019-01-10 Mark Anthony Allen VISUAL DRIVING AID FOR VEHICLE VISOR
BR112020000273A2 (pt) 2017-07-07 2020-07-14 Hanmi Pharm. Co., Ltd. proteína de fusão de enzima e seu método de preparação, composição farmacêutica, polinucleotídeo que codifica a proteína de fusão de enzima, vetor de expressão, transformante
US20200230253A1 (en) 2017-07-28 2020-07-23 HANMl PHARM. CO., LTD. Conjugate of iduronate-2-sulfatase
WO2019032955A1 (en) 2017-08-10 2019-02-14 Denali Therapeutics Inc. MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
WO2019049967A1 (ja) 2017-09-07 2019-03-14 Ｊｃｒファーマ株式会社 水性医薬組成物
CA3076369A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
WO2019140050A1 (en) 2018-01-10 2019-07-18 Denali Therapeutics Inc. Transferrin receptor-binding polypeptides and uses thereof
JP7517997B2 (ja) 2018-06-18 2024-07-17 デナリ セラピューティクス インコーポレイテッド プログラニュリンを含む融合タンパク質
SG11202101273VA (en) 2018-08-16 2021-03-30 Denali Therapeutics Inc Engineered bispecific proteins
KR20210074279A (ko) 2018-08-22 2021-06-21 데날리 테라퓨틱스 인크. 항-her2 폴리펩타이드 및 이의 사용방법
MX2021011612A (es) 2019-04-03 2021-12-10 Denali Therapeutics Inc Formulaciones de moleculas proteicas que comprenden iduronato 2-sulfatasa.
AU2020411480B2 (en) 2019-12-23 2023-12-21 Denali Therapeutics Inc. Progranulin variants
KR20220131246A (ko) 2020-01-13 2022-09-27 데날리 테라퓨틱스 인크. 항-trem2 항체 및 이의 사용 방법
EP4100419A4 (en) 2020-02-07 2024-05-29 Denali Therapeutics Inc. METHODS OF TREATING HUNTER SYNDROME
MA71661A (fr) 2020-10-14 2025-05-30 Denali Therapeutics Inc. Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées

Also Published As

Publication number Publication date
MX2024006720A (es) 2025-04-02
JP2021500857A (ja) 2021-01-14
PE20210347A1 (es) 2021-02-25
PH12020550510A1 (en) 2021-04-19
EP3904389A1 (en) 2021-11-03
JP2023179600A (ja) 2023-12-19
MX2020002918A (es) 2020-07-22
CA3076369A1 (en) 2019-04-11
US10870837B2 (en) 2020-12-22
US20200277584A1 (en) 2020-09-03
WO2019070577A1 (en) 2019-04-11
MX2023009913A (es) 2024-05-21
IL273439B1 (en) 2025-06-01
IL273439A (en) 2020-05-31
MY209029A (en) 2025-06-17
US20190249155A1 (en) 2019-08-15
AU2018345303A1 (en) 2020-04-09
US11866742B2 (en) 2024-01-09
CN111278859A (zh) 2020-06-12
IL273439B2 (en) 2025-10-01
KR20200058510A (ko) 2020-05-27
TW201925236A (zh) 2019-07-01
MA50746A (fr) 2020-08-12
BR112020005271A2 (pt) 2020-09-15
CL2020000810A1 (es) 2020-08-14
EP3692070A1 (en) 2020-08-12
CO2020003128A2 (es) 2020-06-19
CR20200129A (es) 2020-08-22
US20210198640A1 (en) 2021-07-01
SG11202002730XA (en) 2020-04-29
AU2018345303B2 (en) 2025-09-18

Similar Documents

Publication Publication Date Title
SA520411662B1 (ar) بروتينات التحام تشتمل على إنزيمات علاج بديل للإنزيم
EA201891277A1 (ru) Композиции и способы интернализации ферментов
CO2019014682A2 (es) Composiciones y métodos para enzimas de internalización
CL2020003255A1 (es) Proteínas de fusión que comprenden progranulina
AU2017263237A1 (en) GDF15 fusion proteins and uses thereof
MX367024B (es) Proteinas de fusion de enzima lisosomal terapeutica objetivo y usos de las mismas.
MX2018010196A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.
CO2022008648A2 (es) Variantes de progranulina
EA201790178A1 (ru) Пептиды, несущие маннозо-6-фосфат, слитые с лизосомальным ферментом
SG11202000115SA (en) Novel therapeutic enzyme fusion protein and use thereof
MX2023004335A (es) Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas.
ECSP22049014A (es) Variantes de progranulina
MX2019013458A (es) Disminucion de homocisteina mediada por enzimas humanas para el tratamiento de pacientes con hiperhomocisteinemia y homocistinuria.
AR113339A1 (es) Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas (ert) y una región fc
EA202090882A1 (ru) Слитые белки, содержащие ферменты для заместительной ферментной терапии
AR114938A1 (es) Variantes de expresión de cdkl5 y proteínas de fusión cdkl5
UA111147U (uk) Спосіб моделювання гострого асептичного панкреатиту у щурів